|
Market Closed -
Nasdaq
06:00:00 16/06/26 am AEST
|
5-day change | 1st Jan Change | ||
| 23.50 USD | +0.09% |
|
-.--% | +159.10% |
| 17/06 | Assertio Holdings Completes Merger With Zydus Lifesciences | MT |
| 17/06 | Assertio Holdings, Inc. Announces Board and Committee Changes, Effective June 16, 2026 | CI |
| Market Cap | 152M 132M 125M 114M 213M 14.57B 214M 1.5B 578M 7.41B 570M 558M 23.84B | P/E 2024 |
-3.79x | P/E 2025 | -1.91x |
|---|---|---|---|---|---|
| Enterprise Value | 129M 112M 106M 96.23M 180M 12.35B 181M 1.27B 490M 6.28B 483M 473M 20.2B | EV / Sales 2024 |
0.19x | EV / Sales 2025 | 0.3x |
| Free-Float |
99.05% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: Assertio Holdings
| 1 day | +0.09% | ||
| 6 months | +71.28% | ||
| Current year | +159.10% |
| Current year | 9.11 | 23.5 | |
| 1 year | 8.61 | 23.5 | |
| 3 years | 7.71 | 40.5 | |
| 5 years | 7.71 | 120.15 | |
| 10 years | 7.71 | 1,621.19 |
| Director | Title | Age | Since |
|---|---|---|---|
Ravi Yadavar
BRD | Director/Board Member | 26 | 16/06/2026 |
Punit Patel
BRD | Director/Board Member | - | 16/06/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 13/5/26 | Don | Chairman | -13,332 | 0.2069% | ||
| 5/5/26 | Free | Chairman | 4,851 | 0.0753% | ||
| 5/5/26 | Free | Director | 4,851 | 0.0753% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.09% | -.--% | +73.25% | -40.88% | 152M | ||
| +0.04% | +3.34% | +53.32% | +100.52% | 1,028B | ||
| -0.09% | +1.66% | +53.24% | +66.45% | 651B | ||
| -0.02% | +2.66% | +18.65% | +71.97% | 466B | ||
| -1.22% | +3.66% | +34.59% | +38.81% | 346B | ||
| -0.79% | +2.73% | +17.73% | +25.11% | 266B | ||
| +0.58% | +6.76% | +10.58% | +17.75% | 259B | ||
| +1.55% | +2.20% | +35.12% | +45.91% | 208B | ||
| +0.79% | +1.84% | -27.55% | -56.48% | 191B | ||
| -0.52% | +4.45% | +31.57% | +98.11% | 186B | ||
| Average | +0.04% | +2.96% | +30.05% | +36.73% | 360.19B | |
| Weighted average by Cap. | -0.04% | +3.09% | +34.85% | +61.60% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 125M 109M 103M 93.43M 175M 11.99B 176M 1.23B 476M 6.1B 469M 459M 19.62B | 119M 104M 97.74M 88.76M 166M 11.39B 167M 1.17B 452M 5.79B 446M 436M 18.63B |
| Net income | -21.58M -18.82M -17.77M -16.14M -30.23M -2.07B -30.36M -213M -82.14M -1.05B -81.07M -79.27M -3.39B | -30.38M -26.49M -25.01M -22.71M -42.55M -2.91B -42.73M -300M -116M -1.48B -114M -112M -4.77B |
| Net Debt | -59.79M -52.14M -49.23M -44.7M -83.75M -5.74B -84.1M -590M -228M -2.92B -225M -220M -9.38B | -23.15M -20.19M -19.06M -17.31M -32.43M -2.22B -32.57M -228M -88.12M -1.13B -86.97M -85.04M -3.63B |
Employees
53
Sector
Pharmaceuticals
- Stock Market
- Stocks
- ASRT Stock
Select your edition
All financial news and data tailored to specific country editions
















